Loading clinical trials...

Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC) | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)

PHASE 2 STUDY OF AG-013736 AS SECOND-LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CANCER

NCT00569946•Pfizer

View on ClinicalTrials.gov

Summary

To investigate objective tumor response of AG-013736 for metastatic Renal Cell Cancer (mRCC)

Eligibility

Age

20 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients histologically diagnosed as metastatic renal cell cancer with a component of clear cell cancer.
•Patients who are refractory to cytokine therapy as 1st line.
•Patients who experienced nephrectomy.
•Patients with at least 1 target lesion, as defined by RECIST.
•Patients with no uncontrolled hypertension.

Exclusion Criteria

•Gastrointestinal abnormalities
•Current use or anticipated inability to avoid potent CYP3A4 inhibitors or CYP1A2/3A4 inducers.
•Active seizure disorder or evidence of brain metastases.
•Patients with hemoptysis.

Locations (18)

National Cancer Center East Hospital

Kashiwa, Chiba, Japan

Hokkaido University Hospital

Sapporo, Hokkaido, Japan

Tsukuba University Hospital

Tsukuba, Ibaraki, Japan

Iwate Medical University

Morioka, Iwate, Japan

Kochi Medical School Hospital

Nankoku-shi, Kochi, Japan

Kinki University Hospital

Sayama, Osaka, Japan

Hamamatsu University School of Medicine University Hospital

Hamamatsu, Shizuoka, Japan

Shizuoka Cancer Center

Sunto-gun, Shizuoka, Japan

Tokyo Women's Medical University Medical Center East

Arakawa-ku, Tokyo, Japan

National Cancer Center

Chuo-ku, Tokyo, Japan

Key Dates

Start Date

December 12, 2007

Primary Completion Date

February 26, 2010

Completion Date

October 30, 2012

Last Updated

June 5, 2019

Enrollment

ACTUAL participants

Conditions

Carcinoma, Renal Cell

Interventions

AG-013736

DRUG

A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

NCT07227415

Carcinoma, Renal CellAdvanced Renal Cell Carcinoma+11 more

View study

RECRUITINGPHASE2

Autologous Dendritic Cell Vaccine in Kidney Cancer

NCT05127824

Carcinoma, Renal Cell

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 5, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)

Inclusion Criteria

Exclusion Criteria

A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

Autologous Dendritic Cell Vaccine in Kidney Cancer

A Study of Oncobax®-AK in Patients With Advanced Solid Tumors

A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma

A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment